ARAV vs. MBIO, BPTS, AGRX, CYCC, NBY, BPTSY, ARDS, ONCO, VRPX, and CYTO
Should you be buying Aravive stock or one of its competitors? The main competitors of Aravive include Mustang Bio (MBIO), Biophytis (BPTS), Agile Therapeutics (AGRX), Cyclacel Pharmaceuticals (CYCC), NovaBay Pharmaceuticals (NBY), Biophytis (BPTSY), Aridis Pharmaceuticals (ARDS), Onconetix (ONCO), Virpax Pharmaceuticals (VRPX), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical preparations" industry.
Aravive (NASDAQ:ARAV) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
In the previous week, Mustang Bio had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Mustang Bio and 0 mentions for Aravive. Aravive's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.
Mustang Bio has lower revenue, but higher earnings than Aravive. Mustang Bio is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
35.8% of Aravive shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Comparatively, 2.1% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Mustang Bio received 64 more outperform votes than Aravive when rated by MarketBeat users. Likewise, 64.12% of users gave Mustang Bio an outperform vote while only 62.28% of users gave Aravive an outperform vote.
Aravive presently has a consensus target price of $13.50, suggesting a potential upside of 33,565.84%. Mustang Bio has a consensus target price of $17.25, suggesting a potential upside of 6,060.71%. Given Aravive's higher possible upside, equities research analysts plainly believe Aravive is more favorable than Mustang Bio.
Mustang Bio has a net margin of 0.00% compared to Aravive's net margin of -569.65%. Aravive's return on equity of 0.00% beat Mustang Bio's return on equity.
Aravive has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.
Summary
Aravive beats Mustang Bio on 9 of the 16 factors compared between the two stocks.
Get Aravive News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
